Tevogen (TVGN) shared the risk-adjusted net present value estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first clinical-stage product from its proprietary ExacTcell platform. TVGN-489 is being developed for the treatment of SARS-CoV-2 infection in high-risk vulnerable patients and for Long-COVID in patients with evidence of a persistent viral reservoir. “Two cancer patients were able to proceed to stem cell transplant just 15 and 28 days after receiving TVGN-489, a procedure that effectively eliminates the patient’s immune system and requires months for recovery. Remarkably, neither patient experienced reactivation or any complications from COVID-19 during or after transplant. These results strongly suggest that TVGN-489 eradicates the virus both promptly and thoroughly, without evidence of rebound,” said Neal Flomenberg, M.D., Chief Scientific Officer of Tevogen Bio.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- Tevogen finalizes agreement for up to $50M in financing
- Tevogen receives $1M to accelerate AI-driven drug discovery
- Tevogen expanding collaboration with Microsoft and Databricks
- Tevogen signs letter of intent for new cell therapy manufacturing facility
- AI Daily: OpenAI said to end acquisition talks with Windsurf